US Stock Market Closed

Dashboard

Novavax, Inc. (NVAX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity

S

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

CEO

Stanley C. Erck

Employees

165

Industry

Infectious Disease Biopharmaceuticals

Sector

Healthcare

Headquarters

Gaithersburg

Exchange

NASDAQ

Summary Stats

Market Cap

4.21B

Revenue

1.4B

Net Income

-1.32B

EPS

-$17.26

Price-to-Earnings

-3.12

Price-to-Book

64.38

Debt-to-Equity

42.4

News

Analyst Ratings

Price targets projected by 5 analysts

High

$223.00

Average

$186.20

Low

$75.00

Ratings calculated by 6 analysts

Buy

4

Hold

1

Sell

1

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.13

Actual

$2.56 -4.8%

Consensus

2.69

Report Date

Year Ago

-3.05

Year Ago Change %

Up 183%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites